Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Day range

$91.74 – $95.49

Open

$93.63

Prev close

$93.29

Volume

532.4K

Market cap

$7.33B

Shares out

48.84M

P/E

66.90

P/S

7.75

P/B

10.32

P/FCF

37.17

ROE

15.4%

ROA

11.1%

Debt/Equity

0.15

Div yield

0.00%

As of Nov 3, 2026

• Quarterly earningsOct 27, 2026

  On October 27, 2026, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended September 30, 2026.

• Executive compensation changeOct 22, 2026

  In addition, effective January 1, 2027, the Committee approved increases in Mr. Moat's annual base salary and annual target bonus to $700,000 and 60% from $650,000 and 55%, respectively.

• Annual meeting resultsMay 29, 2026

  On May 29, 2026, Kiniksa Pharmaceuticals International, plc (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") at which a quorum was present... The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 6, 2026. Each proposal below was duly passed by the Company's shareholders at the Annual Meeting.

• Executive officer departureMay 1, 2026

  On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry. Mr. Tessari will leave the Company on May 15, 2026.

• Executive officer appointmentJan 14, 2026

  Effective January 10, 2026, the Board of Directors of Kiniksa Pharmaceuticals International, plc (the "Company") appointed Ross Moat to the position of Chief Operating Officer and principal operating officer. Following the appointment, Mr. Moat will continue to oversee the Company's commercial operations, in addition to functional operations under the Chief Operating Officer title.

Days to cover

6.8

Short interest

3.76M

Avg volume

555.48K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock
  positiveZacks Investment Research· Nov 4, 2026
• Breakfast News: We’re Right There With You
  neutralThe Motley Fool· Nov 2, 2026
• Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
  positiveGlobeNewswire Inc.· Jul 28, 2026
• Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today
  positiveThe Motley Fool· Apr 28, 2026
• Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
  positiveGlobeNewswire Inc.· Oct 17, 2025